Patent classifications
C12N2710/16022
VIRAL DETECTION ASSAY
Provided herein are methods for preparing and characterizing CTL cultures and preparations. Also provided herein are methods of determining the presence or absence of trace amounts of viral vectors following the preparation of CTLs.
Enzyme-linked immunoassay to detect <i>Felis catus </i>gammaherpesvirus 1
Indirect ELISAs to detect exposure to Felis catus gammaherpesvirus 1 (FcaGHV1) in domestic cats. These ELISAs detect feline serum antibodies to ORF52 and ORF38 of FcaGHV1. The ELISA assays are sensitive, specific, and adaptable for scale up use in high throughput diagnostics.
Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof
The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.
Expression system for expressing herpesvirus glycoprotein complexes
An expression system for expressing a herpesvirus glycoprotein complex including a vector inserted with two or more nucleic acid sequences that encode two or more subunits of a herpesvirus glycoprotein complex linked by one or more linking sequences such that the subunits are co-expressed simultaneously and self-processed to assemble into a glycoprotein complex. The expression system or the vector can be included in a vaccine composition. The vaccine composition can be used for preventing or treating herpesvirus infections.
RECOMBINANT VIRUS WITH DIMINISHED LATENCY AND METHODS OF USING SAME
The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.
MODIFIED T CELLS AND METHODS OF THEIR USE
The technology described herein relates to modified T cells and their use in immunotherapeutic methods. In various examples, the T cells are modified so as to decrease or eliminate CD3ζ, TRAC, and/or TRBC expression.
GENE-DRIVE IN DNA VIRUSES
In various embodiments methods of utilizing gene drive constructs in asexual organisms such as viruses are provided. In certain embodiments the methods involve transfecting or infecting a cell with a modified DNA vims containing a gene drive construct; and infecting the cell with the target vims where the genome of said target DNA virus is modified by insertion of the gene drive construct into the genome of the target DNA virus and a population of modified target viruses (containing the gene drive construct) is produced.
RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF
The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.
Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof
The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors and polyvalent vaccines comprising the recombinant HVT vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.
EXPRESSION SYSTEM FOR EXPRESSING HERPESVIRUS GLYCOPROTEIN COMPLEXES
Disclosed is an expression system for expressing a herpesvirus glycoprotein complex. The expression system may include a vector inserted with two or more nucleic acid sequences that encode two or more subunits of a herpesvirus glycoprotein complex linked by one or more linking sequences such that the subunits are co-expressed simultaneously and self-processed to assemble into a glycoprotein complex. Also disclosed are vaccine compositions comprising the expression system or the vector and methods of preventing or treating herpesvirus infections using the vaccine compositions.